Is it time to sell Cochlear Limited?

Cochlear Limited (ASX: COH) and ResMed Inc. (CHESS) (ASX: RMD) will always be the sector's best loved stocks but this could be the time for investors to take profit on these great names. Here's why…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bionic ear maker Cochlear Limited (ASX: COH) has advanced 0.7% to $88.57 in late afternoon trade. This could just be the time to take profit.

That's the view of Morgan Stanley, which is warning investors to stand clear of the stock as shares in Cochlear are poised to fall in absolute terms over the next 60 days.

The bearish call comes after the stock's 22% rally over the past six months with Cochlear failing twice to break above $93 a share this calendar year.

Technical analysts who read charts to ascertain future share price performance would see this as an ominous sign, but even those who look at fundamental measures (such as earnings growth and multiples) would be feeling squeamish with the stock trading on a consensus price-earnings (P/E) forecast of 32.3 times for the current financial year and 27.5 times for 2015-16.

I am not saying that Cochlear isn't worth its premium to the market, but its half-year result has left analysts feeling underwhelmed with the company losing market share.

Further, this market share loss is expected to get worse and this is why investors should be wary about paying a premium for the stock.

Of the 14 analysts polled on Reuters, only one thinks the stock is worthy of a "buy" rating and Morgan Stanley thinks earnings downgrades from other brokers are in the wings.

Coincidently, sleep disorder treatment company ResMed Inc. (CHESS) (ASX: RMD) has also left a bad taste in the mouths of investors following its latest earnings result.

Its 1.1% increase in net profit to $91 million in the March quarter has come in under market expectations as gross margins compressed by a stunning 272 basis points (2.72 of a percentage point).

ResMed crashed 9.7% to $8.46 on Friday following the earnings release and is trading flat ahead of the close.

But Macquarie thinks shareholders should use today's stability as a profit taking opportunity and has downgraded the stock to "neutral" from "buy".

I have little doubt that at some stage these great Australian innovators will be a "buy" but I want to see more water pass under their bridges before taking a plunge.

Motley Fool contributor Brendon Lau has no position in any stocks mentioned. Follow me on Twitter - https://twitter.com/brenlau The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »